Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101830 | 0.87 | KMT2A (0.43) | KMT2A | |
| SCHEMBL18309947 | 0.87 | KMT2A (0.43) | KMT2A | |
| SCHEMBL618008 | 0.77 | APP (0.42) | APPCYP2D6ALDH1A1HSD17B10KMT2A | |
| SCHEMBL26988028 | 0.76 | APP (0.41) | APPCYP2D6ALDH1A1HSD17B10KMT2A | |
| SCHEMBL19205339 | 0.76 | APP (0.41) | APPCYP2D6ALDH1A1HSD17B10KMT2A | |
| SCHEMBL3021792 | 0.75 | CYP2D6 (0.44) | CYP2D6CYP1A2ALDH1A1HSD17B10KMT2A | |
| SCHEMBL16415507 | 0.75 | STAT3 (0.42) | APPALDH1A1HSD17B10KMT2ASTAT3 | |
| SCHEMBL3021789 | 0.75 | CYP2D6 (0.44) | CYP2D6CYP1A2ALDH1A1HSD17B10KMT2A | |
| SCHEMBL5501024 | 0.75 | CYP2D6 (0.44) | CYP2D6CYP1A2ALDH1A1HSD17B10KMT2A | |
| SCHEMBL3021790 | 0.75 | CYP2D6 (0.44) | CYP2D6CYP1A2ALDH1A1HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566029-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IP2IPO INNOVATIONS LIMITED (GB) | 2023-01-31 | — | — | US | disclosed |
| US-20210253583-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| US-10927119-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IP2IPO INNOVATIONS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20200055862-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
| US-10414772-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| EP-3107914-B1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECH LTD (GB) | 2019-01-30 | — | — | EP | disclosed |
| US-20180273540-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2018-09-27 | — | — | US | disclosed |
| US-9932344-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| EP-3107914-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-20160362410-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| WO-2015124941-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253583-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK10, CDK1, CDK20 | APP 2517/4885CYP2D6 655/4885CYP1A2 1839/4885 |
| US-10927119-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CDK10, CDK1, CDK20 | APP 2517/4885CYP2D6 655/4885CYP1A2 1839/4885 |
| US-20200055862-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK10, CDK1, CDK20 | APP 2517/4885CYP2D6 655/4885CYP1A2 1839/4885 |
| US-20160362410-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK10, CDK1, CDK20 | APP 557/4885CYP2D6 706/4885CYP1A2 1959/4885 |
| US-20180273540-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK10, CDK1, CDK20 | APP 2517/4885CYP2D6 655/4885CYP1A2 1839/4885 |
| US-11566029-B2 | Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CDK10, CDK1, CDK20 | APP 2517/4885CYP2D6 655/4885CYP1A2 1839/4885 |
| US-10414772-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CDK10, CDK1, CDK20 | APP 2517/4885CYP2D6 655/4885CYP1A2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.